Medical Devices & Surgical Technology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices & Surgical Technology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Analysis confirms benefits of combining trastuzumab and chemotherapy
July 22nd, 2007
A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer. At the ESMO Conference Lugano, Issa Dahabreh from the University of Athens reported the results of a meta-analysis of 5 trials involving more than 13,000 women whose breast cancer was amenable to surgery. All the trials compared disease-free survival, overall survival and the risk of locoregional and distant recurrence of breast cancer in women given adjuvant chemotherapy alone or chemotherapy plus trastuzumab, after breast...
Source: Medical Devices & Surgical Technology Week (2007-07-22)
|
